Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Archana Kumar - Senior Scientist, Small Molecule Analytical Chemistry

Archana Kumar

Senior Scientist, Small Molecule Analytical Chemistry

"My passion is to accelerate the development of novel therapeutics to improve patients’ lives and have an impact on unmet medical needs."
Years at Genentech

I’ve worked in pharmaceutical industry for 15+ years at both small and large organizations. Early in my career, I supported early stage development of API and Drug products. Attracted by Genentech’s focus on science and innovation, I joined the Small Molecule Analytical Chemistry department at Genentech in 2009 and continued leading the analytical chemistry efforts for pre-clinical and early clinical product development. As an analytical project lead, I had the privilege of developing the analytical strategy for several key programs and working with talented colleagues on cross-disciplinary teams.

Since 2014, I have been leading the Process Analytical Group where I am directing analytical chemistry efforts to guide the process chemistry synthetic route development from early stage (pre-clinical) to commercial phase. My team also provides analytical support for the synthetic scale-up activities of API, including in-process control strategy for dose range finding, GLP-tox and clinical campaigns. In this role, my group contributes to nearly every one of our small molecule GDC programs. I enjoy the diversity of science conducted at Genentech as it challenges us and encourages for deeper understanding. I have lead the implementation of Process Analytical Technology (PAT) to enhance process understanding during early development. In addition to PAT, my research interests include trace level genotoxic impurity analysis, rapid elemental analysis and faster separations. I also represent Genentech/Roche on the board of Enabling Technologies Consortium (ETC).